Encyclopedia of AIDS

Living Edition
| Editors: Thomas J. Hope, Douglas Richman, Mario Stevenson

Natural History and Clinical Features of HIV-2 Infection

  • Kevin Peterson
Living reference work entry
DOI: https://doi.org/10.1007/978-1-4614-9610-6_39-1

Definition

A summary of the key literature on the virological, immunological, and clinical progression of HIV-2-infected individuals, with emphasis on the contrast between HIV-2 and HIV-1.

Natural History and Viral Load

The single most distinguishing feature of HIV-2 compared to HIV-1 is its much lower viral load set point. There are no data on the viral loads achieved during the acute phase of HIV-2 infection and less data than for HIV-1 on the viral loads maintained during chronic infection, limiting the precision of viral load estimates at a population level. The viral loads of individuals with untreated chronic HIV-2 infection show considerable variability. While a minority of those infected with HIV-2 have viral burdens typical of progressive HIV-1 infections, in approximately 80 % of HIV-2-infected individuals, viral loads remain very low or, in up to perhaps a third of cases, undetectable (Grant et al. 1997; van der Loeff et al. 2010). This is in contrast to HIV-1, where only 1...

Keywords

Cervical Cancer Viral Load Undetectable Viral Load Dual Infection Viral Load Measurement 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Ariyoshi K, Schim van der Loeff M, et al. Kaposi’s sarcoma in the Gambia, West Africa is less frequent in human immunodeficiency virus type 2 than in human immunodeficiency virus type 1 infection despite a high prevalence of human herpesvirus 8. J Hum Virol. 1998;1(3):193–9.PubMedGoogle Scholar
  2. Ariyoshi K, Jaffar S, et al. Plasma RNA viral load predicts the rate of CD4 T cell decline and death in HIV-2-infected patients in West Africa. AIDS. 2000;14(4):339–44.CrossRefPubMedGoogle Scholar
  3. Camacho RJ. Special aspects of the treatment of HIV-2-infected patients. Intervirology. 2012;55(2):179–83.CrossRefPubMedGoogle Scholar
  4. de Silva TI, Cotten M, et al. HIV-2: the forgotten AIDS virus. Trends Microbiol. 2008;16(12):588–95.CrossRefPubMedGoogle Scholar
  5. de Silva T, Leligdowicz A, et al. Effect of HIV-2 infection on HIV-1 disease progression. N Engl J Med. 2012;367(20):1961–2. author reply 1962–1963.CrossRefPubMedGoogle Scholar
  6. de Silva TI, van Tienen C, et al. Population dynamics of HIV-2 in rural West Africa: comparison with HIV-1 and ongoing transmission at the heart of the epidemic. AIDS. 2013;27(1):125–34.CrossRefPubMedGoogle Scholar
  7. Drylewicz J, Eholie S, et al. First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration. AIDS. 2010;24(7):1043–50.CrossRefPubMedPubMedCentralGoogle Scholar
  8. Esbjornsson J, Mansson F, et al. Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection. N Engl J Med. 2012;367(3):224–32.CrossRefPubMedGoogle Scholar
  9. Gottlieb GS, Sow PS, et al. Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. J Infect Dis. 2002;185(7):905–14.CrossRefPubMedGoogle Scholar
  10. Gottlieb GS, Hawes SE, et al. Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission. AIDS. 2006;20(6):895–900.CrossRefPubMedPubMedCentralGoogle Scholar
  11. Grant AD, Djomand G, et al. Natural history and spectrum of disease in adults with HIV/AIDS in Africa. AIDS. 1997;11(Suppl B):S43–54.PubMedGoogle Scholar
  12. Hawes SE, Critchlow CW, et al. Incident high-grade squamous intraepithelial lesions in Senegalese women with and without human immunodeficiency virus type 1 (HIV-1) and HIV-2. J Natl Cancer Inst. 2006;98(2):100–9.CrossRefPubMedGoogle Scholar
  13. Jaffar S, Grant AD, et al. The natural history of HIV-1 and HIV-2 infections in adults in Africa: a literature review. Bull World Health Organ. 2004;82(6):462–9.PubMedPubMedCentralGoogle Scholar
  14. Leligdowicz A, Rowland-Jones S. Tenets of protection from progression to AIDS: lessons from the immune responses to HIV-2 infection. Expert Rev Vaccines. 2008;7(3):319–31.CrossRefPubMedGoogle Scholar
  15. Lucas SB, Hounnou A, et al. The mortality and pathology of HIV infection in a west African city. AIDS. 1993;7(12):1569–79.CrossRefPubMedGoogle Scholar
  16. MacNeil A, Sarr AD, et al. Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. J Virol. 2007;81(10):5325–30.CrossRefPubMedPubMedCentralGoogle Scholar
  17. Martinez-Steele E, Awasana AA, et al. Is HIV-2- induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic. AIDS. 2007;21(3):317–24.CrossRefPubMedGoogle Scholar
  18. Ndour M, Sow PS, et al. AIDS caused by HIV1 and HIV2 infection: are there clinical differences? Results of AIDS surveillance 1986–97 at Fann Hospital in Dakar, Senegal. Tropical Med Int Health. 2000;5(10):687–91.CrossRefGoogle Scholar
  19. Peterson I, Togun O, et al. Mortality and immunovirological outcomes on antiretroviral therapy in HIV-1 and HIV-2-infected individuals in the Gambia. AIDS. 2011a;25(17):2167–75.CrossRefPubMedGoogle Scholar
  20. Peterson K, Jallow S, et al. Antiretroviral therapy for HIV-2 infection: recommendations for management in low-resource settings. AIDS Res Treat. 2011b;2011:463704.PubMedPubMedCentralGoogle Scholar
  21. Saksena NK, Rodes B, et al. Elite HIV controllers: myth or reality? AIDS Rev. 2007;9(4):195–207.PubMedGoogle Scholar
  22. van der Loeff MF, Larke N, et al. Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village. Retrovirology. 2010;7:46.CrossRefPubMedPubMedCentralGoogle Scholar
  23. Weiss R, Boshoff C. Addressing controversies over Kaposi’s sarcoma. J Natl Cancer Inst. 2000;92(9):677–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of Clinical SciencesInstitute of Tropical MedicineAntwerpBelgium
  2. 2.Department of Epidemiology and Social Medicine, Faculty of Medical SciencesUniversity of AntwerpAntwerpBelgium